RESUMO
INTRODUCTION: Being elderly is a well-known risk factor for candidemia, but few data are available on the prognostic impact of candidemia in the very old (VO) subjects, as defined as people aged ≥75 years. OBJECTIVE: The aim of this study was to assess risk factors for nosocomial candidemia in two groups of candidemia patients, consisting of VO patients (≥75 years) and adult and old (AO) patients (18-74 years). In addition, risk factors for death (30-day mortality) were analysed separately in the two groups. METHODS: We included all consecutive candidemia episodes from January 2011 to December 2013 occurring in six referral hospitals in north-eastern Italy. RESULTS: A total of 683 nosocomial candidemia episodes occurred. Of those, 293 (42.9%) episodes were in VO and 390 (57.1%) in AO patients. Hospitalization in medical wards, chronic renal failure, urinary catheter, and peripheral parenteral nutrition (PPN) were more common in VO than in AO patients. In the former patient group, adequate antifungal therapy (73.2%) and central venous catheter (CVC) removal (67.6%) occurred less frequently than in AO patients (82.5 and 80%, p < 0.002 and p < 0.004, respectively). Thirty-day mortality was higher in VO compared to AO patients (47.8 vs. 23.6%, p < 0.0001). In AO patients, independent risk factors for death were age (OR 1.04, 95% CI 1.00-1.09, p = 0.038), recent history of chemotherapy (OR 22.01, 95% CI 3.12-155.20, p = 0.002), and severity of sepsis (OR 40.68, 95% CI 7.42-223.10, p < 0.001); CVC removal was associated with higher probability of survival (OR 0.10, 95% CI 0.03-0.33, p < 0.001). In VO patients, independent risk factors for death were PPN (OR 3.5, 95% CI 1.17-10.47, p = 0.025) and hospitalization in medical wards (OR 2.58, 95% CI 1.02-6.53, p = 0.046), while CVC removal was associated with improved survival (OR 0.40, 95% CI 0.16-1.00, p = 0.050). CONCLUSION: Thirty-day mortality was high among VO patients and was associated with inadequate management of candidemia, especially in medical wards.
Assuntos
Candidemia/tratamento farmacológico , Candidemia/mortalidade , Infecção Hospitalar , Adulto , Idoso , Idoso de 80 Anos ou mais , Candidemia/microbiologia , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/mortalidade , Feminino , Hospitais/estatística & dados numéricos , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
PURPOSE: Risk factors for nosocomial candidemia, severity of sepsis, treatment, and outcome were compared between patients admitted to medicine wards and those to surgical and intensive care units (ICUs). METHODS: Data were retrospectively collected from patients belonging to six referral hospitals in Italy between January 2011 and December 2013. Risk factors for 30-day mortality were evaluated in the whole patient population. RESULTS: A total of 686 patients (mean age 70 ± 15 years) with candidemia were included. 367 (53.5 %) patients were in medicine wards, and 319 in surgery and ICUs. Host-related risk factors for candidemia were more common in medicine patients whereas healthcare-related factors in surgery/ICU patients. These patients showed severe sepsis and septic shock more commonly (71.7 %) than medicine patients (59.9 %) (p 0.003). The latter underwent central venous catheter (CVC) removal and adequate antifungal therapy less frequently than surgery/ICU patients. 149 (40.6 %) patients died with candidemia in medicine wards and 69 (21.6 %) in other wards (p < 0.001). Overall, the 30-day mortality was 36.3 %. At multivariate analysis, independent risk factors for death were aging, higher Charlson score, severe sepsis and septic shock, and no antifungal therapy, while major surgery and CVC removal were associated with higher probability of survival. CONCLUSIONS: The burden of risk factors for candidemia was different between medicine patients and those in other wards. Despite the lower severity of candidemia in medicine patients, their mortality turned out to be higher than in surgery or ICU patients. Awareness of the best management of candidemia should be pursued, especially in medicine wards.
Assuntos
Candidemia/epidemiologia , Infecção Hospitalar/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Feminino , Unidades Hospitalares , Humanos , Itália/epidemiologia , Masculino , Estudos Retrospectivos , Fatores de RiscoRESUMO
BACKGROUND: Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) is a rare and severe adverse drug reaction with an associated mortality of 10-20%. Clinical worsening despite discontinuation of the culprit drug is considered a characteristic feature of DIHS/DRESS. Besides the early recognition of the syndrome and discontinuation of its causative drug, the mainstay of treatment is systemic corticosteroids. Nevertheless, treatment of severe DIHS/DRESS is not well defined, as corticosteroids may sometimes not be effective, and decreasing the dose may be associated with flaring of the disease. CASE REPORT: A 38-year-old woman with high fever, malaise, abdominal pain, rash, and elevated liver enzymes received immediate high-dose N-acetylcysteine, because acetaminophen hepatotoxicity was suspected. N-acetylcysteine administration was associated with a significant clinical improvement. However, within the next week DIHS/DRESS syndrome was diagnosed, which explained all the symptoms, and which was subsequently treated with prednisone and valganciclovir. CONCLUSIONS: New options necessary to improve treatment of severe DIHD/DRESS have to consider its sequential pathogenetic mechanisms. N-acetylcysteine might neutralize the drug-derived reactive metabolites, which are responsible for protein adduct formation and specific T cell stimulation, and replete the glutathione stores that counterbalance oxidative stress. Prednisone might inhibit lymphoproliferation and valganciclovir might prevent complications related to HHV-6 reactivation. We therefore propose the unprecedented combination of N-acetylcysteine, prednisone and valganciclovir as a treatment option for DIHS/DRESS.
Assuntos
Acetilcisteína/uso terapêutico , Hipersensibilidade a Drogas/tratamento farmacológico , Eosinofilia/tratamento farmacológico , Ganciclovir/análogos & derivados , Modelos Biológicos , Prednisona/uso terapêutico , Adulto , Hipersensibilidade a Drogas/complicações , Quimioterapia Combinada , Eosinofilia/complicações , Feminino , Ganciclovir/uso terapêutico , Humanos , ValganciclovirRESUMO
COVID-19 is characterized by a severe pulmonary disease due to severe acute respiratory syndrome (SARS)-CoV-2 infection. For clinicians involved in the management of patients with chronic autoimmune diseases the risk linked to the conditions itself and to drug-induced immunosuppression during the COVID-19 pandemic is a major topic. Pemphigus is a rare autoimmune blistering disease (AIBD) of the skin and mucous membranes caused by autoantibodies to desmosomal components, desmoglein 1 and 3. Among immunosuppressant therapies, rituximab (RTX) is considered a highly effective treatment with a favorable safety profile, but it induces a prolonged B-cell depletion that can lead to higher susceptibility to infections. For this reason, concerns about its use during the pandemic have been raised. We describe a case of a pemphigus patient in which RTX-induced B cell depletion led to the severe inflammatory phase, whereas corticosteroid treatment allowed a favorable outcome.
Assuntos
Corticosteroides/uso terapêutico , Linfócitos B/imunologia , Tratamento Farmacológico da COVID-19 , Pênfigo/imunologia , Rituximab/efeitos adversos , Corticosteroides/efeitos adversos , Linfócitos B/metabolismo , COVID-19/complicações , COVID-19/fisiopatologia , Feminino , Febre , Humanos , Imunoglobulina G/imunologia , Inflamação/tratamento farmacológico , Pessoa de Meia-Idade , Oxigenoterapia , Pênfigo/complicações , Pênfigo/tratamento farmacológico , Rituximab/uso terapêuticoRESUMO
Toxigenic Clostridium difficile is responsible for antibiotic-associated diarrhoea and other diseases. The increasing frequency and severity is attributed to highly-virulent ribotypes such as 027. The aim of the study was to collect epidemiological and molecular data for C. difficile isolates during 2009-2013 in the Central Hospital of Bolzano, Northern Italy. Stool samples from inpatients of the Bolzano Central Hospital were screened for toxins A and B, and C. difficile was cultured and tested for antibiotic susceptibility. PCRs were performed for genes of toxin A, toxin B, binary toxin and ribotyping. During the period 2009-13 from 320 patients (9% of patients tested) at least one stool sample proved positive for C. difficile toxins, and incidences for all hospital inpatients per 10,000 patient days (per 1,000 admissions) varied between 2.2 (1.5) and 4.3 (3.0). Out of 138 isolates (43% of total isolates were studied), 24 different ribotypes were identified. Isolates with ribotype 027 were predominant (38%), followed by 018 (13%) and 607 (10%). Whereas for ribotype 018 a significant decrease was seen during the five-year period, ribotype 027 increased significantly from 0% in 2009 to 64% in 2012, decreasing then to 10% in 2013. Isolates were sensitive to metronidazole and vancomycin, whereas isolates of the three major ribotypes were resistant to moxifloxacin. Our data indicates a significant change in C. difficile incidence rates and ribotype frequencies during the five-year period in the Central Hospital in Bolzano.
Assuntos
Clostridioides difficile/isolamento & purificação , Infecções por Clostridium/diagnóstico , Infecções por Clostridium/epidemiologia , Pacientes Internados/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Clostridioides difficile/classificação , Clostridioides difficile/genética , Infecções por Clostridium/complicações , Infecções por Clostridium/genética , Diarreia/microbiologia , Farmacorresistência Bacteriana/genética , Feminino , Humanos , Incidência , Itália/epidemiologia , Masculino , Testes de Sensibilidade Microbiana/métodos , Pessoa de Meia-Idade , Estudos Retrospectivos , RibotipagemAssuntos
Acetamidas/uso terapêutico , Anti-Infecciosos/uso terapêutico , Infecções Oculares Bacterianas/tratamento farmacológico , Staphylococcus aureus Resistente à Meticilina , Celulite Orbitária/tratamento farmacológico , Oxazolidinonas/uso terapêutico , Rifampina/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Quimioterapia Combinada , Infecções Oculares Bacterianas/microbiologia , Humanos , Linezolida , Celulite Orbitária/microbiologia , Retratamento , Infecções Estafilocócicas/microbiologia , Tomografia Computadorizada por Raios X , Resultado do TratamentoAssuntos
Antifúngicos/uso terapêutico , Candidíase/tratamento farmacológico , Endoftalmite/tratamento farmacológico , Infecções Oculares Fúngicas/tratamento farmacológico , Hospedeiro Imunocomprometido , Complicações Pós-Operatórias , Anfotericina B/uso terapêutico , Candidíase/microbiologia , Endoftalmite/microbiologia , Infecções Oculares Fúngicas/microbiologia , Humanos , Pirimidinas/uso terapêutico , Recidiva , Triazóis/uso terapêutico , VoriconazolRESUMO
A 43 year old man with HIV and HCV infection and liver cirrhosis developed fatal lactic acidosis within five days from starting nifedipine for arterial hypertension. Multiple drug interactions, current and accumulated drug toxicities and the reduced liver function, might in combination have led to the acute lactic acidosis.
Assuntos
Acidose Láctica/induzido quimicamente , Dissuasores de Álcool/efeitos adversos , Antirretrovirais/efeitos adversos , Anti-Hipertensivos/efeitos adversos , Dissulfiram/efeitos adversos , Infecções por HIV/tratamento farmacológico , Hepatite C/complicações , Hipertensão/tratamento farmacológico , Nifedipino/efeitos adversos , Acidose Láctica/metabolismo , Adulto , Dissuasores de Álcool/farmacocinética , Alcoolismo/complicações , Alcoolismo/tratamento farmacológico , Antirretrovirais/farmacocinética , Anti-Hipertensivos/farmacocinética , Terapia Antirretroviral de Alta Atividade , Dissulfiram/farmacocinética , Interações Medicamentosas , Evolução Fatal , Infecções por HIV/complicações , Humanos , Hipertensão/induzido quimicamente , Fígado/efeitos dos fármacos , Fígado/enzimologia , Cirrose Hepática/etiologia , Masculino , Insuficiência de Múltiplos Órgãos/induzido quimicamente , Nifedipino/farmacocinéticaRESUMO
A 39-y-old male had a diagnosis of sarcoidosis and corticosteroid therapy was started. Surprisingly, following his discharge from hospital, Mycobacterium marinum was isolated in 1 of 3 sputum samples taken 7 weeks earlier on admission. After this, Mycobacterium marinum-DNA was identified in the stored lung biopsies by the PCR-RFLP of the hsp65 gene.
Assuntos
Infecções por Mycobacterium não Tuberculosas/complicações , Mycobacterium marinum/isolamento & purificação , Sarcoidose/etiologia , Adulto , Proteínas de Bactérias/genética , Chaperonina 60 , Chaperoninas/genética , Humanos , Masculino , Infecções por Mycobacterium não Tuberculosas/diagnóstico , Mycobacterium marinum/classificação , Mycobacterium marinum/patogenicidade , Sarcoidose/microbiologiaRESUMO
Shewanella putrefaciens is as yet rarely responsible for clinical syndromes in humans. However, a case involving multiple organs in an elderly male under treatment with appropriate steroids confirms that attention should be devoted to unusual pathogens.